Baird Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $280

Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price target from $252 to $280.